Drug Profile
Research programme: herpes simplex virus type 2 vaccines - Nykode Therapeutics
Latest Information Update: 03 Dec 2021
Price :
$50
*
At a glance
- Originator Vaccibody
- Developer Nykode Therapeutics
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Herpes simplex virus type 2 infections
Most Recent Events
- 23 Nov 2021 Vaccibody is now called Nykode Therapeutics
- 28 Aug 2020 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections(Prevention) in Norway (Parenteral, Injection)
- 05 Jul 2016 Preclinical trials in Herpes simplex virus type-2 infections (Prevention) in Norway (Parenteral, injection)